SH2 domain-containing phosphatase 2 (SHP2)

SH2 domain-containing phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a cytoplasmic protein tyrosine phosphatase containing two SH2 (Src homology 2) domains at its N-terminus and a catalytic PTP domain at its C-terminus[5][4][2]. SHP2 is a central signaling enzyme involved in the regulation of multiple growth factor and cytokine pathways across diverse tissues, with key roles in cell proliferation, differentiation, migration, and survival[5][4][2][3]. Under basal conditions, SHP2 is autoinhibited by intramolecular binding of the N-SH2 domain to the PTP domain, blocking the catalytic site[2][3][4]. Upon engagement of the SH2 domains by phosphotyrosine-containing motifs (typically on activated receptors), the enzyme undergoes a conformational switch to its active form, allowing substrate dephosphorylation and signal propagation[2][3][4]. SHP2 positively regulates mitogen-activated protein kinase (MAPK/ERK) signaling, distinguishing it from many other phosphatases that act as signal dampeners[3][5]. Mutations in PTPN11 are associated with several malignancies (such as juvenile myelomonocytic leukemia), developmental syndromes (notably Noonan syndrome), and, by deregulating growth pathways, contribute to cancer cell survival, drug resistance, and immune evasion[2][5]. Owing to its oncogenic and disease-related roles, SHP2 is a validated therapeutic target, and multiple small-molecule SHP2 inhibitors are in clinical or preclinical development. Key safety concerns include on-target toxicity due to disruption of essential cellular signaling in normal tissues[5][4][2][3].

Other names

SHP2PTPN11Protein tyrosine phosphatase non-receptor type 11SH-PTP2PTP1D

Allosteric inhibition, Catalytic site inhibition